Li Ning Li
Direktor/Vorstandsmitglied bei HaploX Investment Holding Ltd.
Profil
Li Ning Li is a professional who currently holds a Non-Executive Director position at HaploX Investment Holding Ltd.
Prior to this, she worked as a Director of Operations at Grains Valley Venture Capital in 2009.
Ms. Li graduated from the University of Cardiff in 2006 with a graduate degree and from China Pharmaceutical University in 1998 with an undergraduate degree.
Aktive Positionen von Li Ning Li
| Unternehmen | Position | Beginn |
|---|---|---|
HaploX Investment Holding Ltd.
 HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Direktor/Vorstandsmitglied | 29.01.2023 |
Ehemalige bekannte Positionen von Li Ning Li
| Unternehmen | Position | Ende |
|---|---|---|
| Grains Valley Venture Capital | Geschäftsführer | 02.01.2009 |
Ausbildung von Li Ning Li
| University of Cardiff | Graduate Degree |
| China Pharmaceutical University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| Grains Valley Venture Capital | |
HaploX Investment Holding Ltd.
HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Commercial Services |
